| 回购方案首次披露日 | 2024 年 7 月 5 日 | | | --- | --- | --- | | 回购方案实施期限 | 2024 年 6 月 17 日-2025 | 年 6 月 16 日 | | 预计回购金额 | 2000 万元-4000 万元 | | | 回购用途 | 用于员工持股计划或股权激励 | | | 累计已回购股数 | 372,145 股 | | | 累计已回购股数占总股本比例 | 0.097% | | | 累计已回购金额 | 5,038,831.40 元 | | | 实际回购价格区间 | 12.09 元/股-14.16 | 元/股 | 重要内容提示： 一、 回购股份的基本信息 公司于 2024 年 6 月 17 日召开第五届董事会第十四次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过上海证 券交易所交易系统以集中竞价交易方式回购公司已发行的部分人民币普通股股票， 拟用于实施员工持股计划/或股权激励计划。用于本次回购的资金总额不低于人民币 2,000.00 万元、不超过人民币 4,000.00 万元，以不超过人民币 28.56 元/股的价格 进 ...

致：香港交易及結算所有限公司 截至月份: 2024年9月30日 狀態: 新提交 第 1 頁 共 10 頁 v 1.1.0 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 公司名稱: 北京市春立正達醫療器械股份有限公司 FF301 | | | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 688236 | 說明 | | 於上海證券交易所上市的A股 | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 288,428,000 | RMB | | 1 RMB | | 288,428,000 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 288,428,000 | RMB | | 1 RMB | | 288,428,000 | | 1. 股份分 ...

FF305 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 北京市春立正達醫療器械股份有限公司 呈交日期： 2024年9月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市 ...

Product Development and Innovation - The company focuses on orthopedic medical devices and tissue repair products, including spinal, trauma, joint, and sports medicine implants, as well as surgical instruments and PRP preparation kits[7]. - The company is investing in R&D for new materials such as porous tantalum and PEEK, and enhancing product lines in surgical robotics, sports medicine, PRP, and oral health[8]. - The company is continuously innovating and expanding its diversified product lines to adapt to the evolving orthopedic market[7]. - The company is focused on maintaining a competitive edge in the orthopedic high-value consumables sector through strategic R&D investments[8]. - The company aims to enhance its product reserve by seeking advanced technologies and excellent products in related fields, ensuring sustainable development in the medical sector[8]. - The company has launched new products in the artificial joint field, including femoral head reconstruction rods and porous tantalum metal implants, which will further increase its market share in the artificial joint sector[9]. - The company has developed a comprehensive oral product line, including dental implants and orthodontic products, aiming to provide a one-stop solution for various dental needs[9]. - The company has successfully developed a handheld orthopedic robot system, which improves surgical precision and promotes minimally invasive, intelligent, and digital orthopedic surgeries[10]. - The company has launched an all-automatic PRP preparation system, marking a significant advancement in its PRP product matrix, which is the first of its kind in China[9]. - The company is focusing on customized, minimally invasive, and intelligent orthopedic medical devices to meet the growing demand in the market[40]. - The company has a full range of customized joint technologies, including 3D-printed joint osteotomy guides, aimed at improving surgical accuracy and patient satisfaction[40]. Market Expansion and Competitive Position - In May 2024, the company won bids for three hip joint products and the entire knee joint system in the centralized procurement in Tianjin[7]. - All eight product categories submitted by the company for spinal materials were awarded in the national centralized procurement organized in 2023[7]. - The company is actively expanding its marketing network to increase market share in the sports medicine field, with a total demand share increase expected from the upcoming procurement in November 2023[7]. - The orthopedic implant market is expected to grow due to factors such as aging population, increasing healthcare spending, and improved public medical infrastructure in China[7]. - The company aims to enhance its comprehensive competitiveness by continuously meeting diverse market and clinical demands through its extensive product registrations and innovations[10]. - The company is committed to expanding its international market presence while maintaining its leading position in the domestic market[40]. Financial Performance - The company's operating revenue for the six months ended June 30, 2024, was approximately RMB 380.13 million, a decrease of 29.70% compared to RMB 540.71 million in the same period last year[15]. - The gross profit for the same period was approximately RMB 271.88 million, down 30.54% from RMB 391.41 million year-on-year[17]. - The net profit attributable to shareholders for the six months ended June 30, 2024, was RMB 79.03 million, a decline of 37.32% from RMB 126.08 million in the previous year[25]. - Research and development expenses for the first half of 2024 were approximately RMB 67.66 million, representing 17.80% of revenue, compared to 13.79% in the same period last year[20]. - Sales expenses for the six months ended June 30, 2024, were approximately RMB 111.48 million, a decrease of 33.20% from RMB 166.89 million in the previous year[18]. - The company reported a decrease in credit impairment losses to approximately RMB 5.79 million, down 34.13% from RMB 8.79 million year-on-year, due to a reduction in accounts receivable[21]. - The company achieved a net profit attributable to shareholders of RMB 79,026,078.82 for the first half of 2024[46]. - The total comprehensive income attributable to the parent company is RMB 79.03 million, a decrease of 37.3% from RMB 126.08 million in the previous period[71]. Assets and Liabilities - As of June 30, 2024, the company held a total of 606 domestic intellectual property rights, including 124 invention patents and 468 utility model patents[12]. - The company has no significant contingent liabilities or guarantees as of June 30, 2024[34]. - Accounts receivable increased from approximately RMB 358.3 million as of December 31, 2023, to approximately RMB 757.4 million as of June 30, 2024, due to changes in collection methods[29]. - Inventory rose from approximately RMB 4.3449 billion as of December 31, 2023, to approximately RMB 5.204 billion as of June 30, 2024, driven by product stockpiling based on market demand[30]. - Current assets decreased from approximately RMB 23.2869 billion as of December 31, 2023, to approximately RMB 22.7349 billion as of June 30, 2024, primarily due to the provision for dividends[32]. - The total assets at the end of the period amount to RMB 3,621,698,636.05, down from RMB 3,645,326,641.07 at the beginning of the period, reflecting a decrease of 0.65%[66]. - The total liabilities increased to RMB 829,644,175.77 from RMB 792,843,181.35, representing an increase of 4.6%[66]. - The company's total equity decreased to RMB 2,792,054,460.28 from RMB 2,852,483,459.72, reflecting a decrease of 2.1%[66]. Corporate Governance and Compliance - The company has maintained compliance with the corporate governance code as per the Hong Kong Listing Rules during the reporting period[47]. - All directors and supervisors confirmed compliance with the standard code of conduct for securities trading during the six months ending June 30, 2024[48]. - The audit committee has reviewed the consolidated financial statements for the six months ending June 30, 2024[49]. - The financial report was approved by the board of directors on August 30, 2024, indicating timely governance and oversight[89]. Employee and Talent Management - The company has established an effective incentive mechanism to motivate employees and attract high-quality talent through a competitive compensation system[43]. - As of June 30, 2024, the company employed approximately 1,291 staff, with total employee compensation and related costs amounting to RMB 151.56 million[44]. Accounting Policies and Financial Reporting - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect a true and complete picture of its financial status as of June 30, 2024[92]. - The company’s accounting policies and estimates are based on the actual transactions and events, ensuring compliance with relevant accounting standards[90]. - The company follows a control-based approach for determining the scope of consolidated financial statements, requiring power over the investee, variable returns, and the ability to influence returns[97]. - Consolidated financial statements are prepared using uniform accounting policies and periods for parent and subsidiaries, with necessary adjustments made for inconsistencies[98]. - The company recognizes revenue when it fulfills its performance obligations, which occurs when the customer obtains control of the related goods or services[146].

北京市春立正达医疗器械股份有限公司 关于召开 2024 年第一次临时股东大会的通知 证券代码：688236 证券简称：春立医疗 公告编号：2024-036 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年第一次临时股东大会 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2024 年 10 月 15 日 14 点 00 分 召开地点：北京市通州区通州经济开发区南区鑫觅西二路 10 号 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自 2024 年 10 月 15 日 至 2024 年 10 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股东 大会召开当日的交易时间段，即 9:15-9:25,9:30-11:30，13:00-15 ...

北京市春立正达医疗器械股份有限公司 股东大会会议资料 H 股代码：01858 A 股代码：688236 证券简称：春立医疗 北京市春立正达医疗器械股份有限公司 2024 年第一次临时股东大会 会议资料 二〇二四年十月 1 | 会议须知 3 | | --- | | 会议议程 5 | | 会议议案 7 | | 议案一：《关于公司 2024 年半年度利润分配方案的议案》 7 | | 议案二：《关于公司募投项目延期及变更的议案》 8 | 北京市春立正达医疗器械股份有限公司 股东大会会议资料 北京市春立正达医疗器械股份有限公司 2024 年第一次临时股东大会 会议须知 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的顺利 进行，根据《中华人民共和国公司法》、《中华人民共和国证券法》、《上市公司股东大会 规则》以及《北京市春立正达医疗器械股份有限公司章程》以及《北京市春立正达医疗器械 股份有限公司股东大会议事规则》等相关规定，特制定本会议须知, 请全体出席股东大会的 人员自觉遵守： 五、要求发言的股东及股东代理人，应提前在股东大会签到处进行登记，会议进行中只 接受股东及股东代理人发言或提问，股东现 ...

华泰联合证券有限责任公司 关于北京市春立正达医疗器械股份有限公司 2024 年半年度持续督导跟踪报告 | 保荐机构名称： | 被保荐公司简称： | | --- | --- | | 华泰联合证券有限责任公司 | 北京市春立正达医疗器械股份有限公司 | | 保荐代表人姓名：张畅 | 联系电话：010-56839300 | | 保荐代表人姓名：胡明峰 | 联系电话：010-56839300 | 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为北京市春立正达医疗器械股份有 限公司（以下简称"春立医疗"、"公司"或"发行人"）首次 A 股公开发行股 票的保荐机构，对春立医疗进行持续督导，并出具本持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 经公司自查及保荐机构督导发现，公司在 2023 年 10 月 30 日至 2024 年 1 月 16 日、2024 年 1 月 18 日至 2024 年 3 月 11 日存在使用闲置募集资金进行现金管 理的额度超出了第五届董事会第五 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 14.91 CNY, based on a 21x PE valuation for 2024 [1][4]. Core Views - The company's performance is under short-term pressure due to the implementation of national high-value consumables procurement, leading to a revenue of 380 million CNY in H1 2024, a year-on-year decrease of 29.7%, and a net profit of 79 million CNY, down 37.3% [1]. - The company is actively responding to procurement policies by enhancing its marketing system and has successfully won bids for its hip and knee joint products in the recent procurement results [1]. - New product approvals are enhancing the company's product strength, with significant R&D investments leading to the launch of several innovative products in various medical fields [1]. Financial Summary - Revenue for 2024 is projected at 1,280 million CNY, with a growth rate of 5.9% [3]. - The net profit attributable to the parent company is expected to be 273 million CNY in 2024, reflecting a slight decline of 1.6% [3]. - The earnings per share (EPS) forecast for 2024 is 0.71 CNY, with subsequent years projected at 0.89 CNY for 2025 and 1.00 CNY for 2026 [1][3].

证券研究报告 | 2024年09月10日 春立医疗（688236.SH） 优于大市 业绩受集采执行影响有所承压，研发投入保持高强度 业绩受国家集采执行影响有所承压，上半年外销业务表现亮眼。2024 年上半 年公司实现营收 3.80 亿（-29.7%），归母净利润 0.79 亿（-37.3%），扣非 归母净利润 0.66 亿（-40.3%）。单二季度实现营收 1.58 亿（-46.2%），环 比下降 28.7%，归母净利润 0.24 亿（-66.1%），环比下降 56.8%。二季度业 绩显著承压，主要是受到国家高值耗材集采落地实施的影响。上半年公司主 营业务外销收入达 1.55 亿，占整体营收比例为 40.7%，已成为支撑公司发展 的重要驱动力。 毛净利率有所下滑，管理及研发费用率有一定提升。2024 年上半年公司毛利 率为 71.5%（-0.9pp）。销售费用率 29.3%（-1.5pp），主要由于市场开拓 费下降；管理费用率 5.6%（+2.1pp），研发费用率 17.8%（+4.0pp），财务 费用率-2.4%（-1.5pp）。公司净利率为 20.8%（-2.5pp），盈利能力有所承 压。2024 年上半 ...

Investment Rating - The report maintains a "Recommended" rating for the company with a target price of 18 yuan, compared to the current price of 10.83 yuan [1]. Core Insights - The company's performance in the first half of 2024 was impacted by centralized procurement policies, leading to a significant decline in revenue and net profit [2]. - Despite the challenges, the gross margin remained stable at 71.52%, and the company continues to invest heavily in research and development [2]. - The company has successfully expanded its product line, receiving multiple certifications for new products in various medical fields [2]. - International revenue showed strong growth, accounting for 40.7% of total revenue in the first half of 2024, a significant increase from the previous year [2]. - Future growth is anticipated as the impact of centralized procurement is expected to diminish, alongside increasing domestic orthopedic surgery volumes and rapid overseas expansion [2]. Financial Summary - Total revenue for H1 2024 was 380 million yuan, a decrease of 29.70% year-on-year, with a net profit of 79 million yuan, down 37.32% [1][2]. - The company forecasts net profits of 270 million yuan, 330 million yuan, and 390 million yuan for 2024, 2025, and 2026, respectively, with corresponding EPS of 0.71, 0.85, and 1.01 yuan [2][3]. - The projected P/E ratios for the next three years are 15, 13, and 11 times [3].